EUVIMEDObjevte EUVIMED
Crossref

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation

Wesley J Hoffmann iD, Shemual Tsai iD, Luma Succar iD, Aarjav Sanghvi iD, Stephen L Jones iD, Ashton A Connor iD, Constance M Mobley iD, R Mark Ghobrial iD, Masayuki Nigo iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-07 · 46 (7)

DOI: 10.1002/phar.70176 ↗

At a glance

Journal article in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2026-06-10. Written by Wesley J Hoffmann and 8 co-authors. Institution: Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA. Major MEDLINE topics: Voriconazole, Drug Monitoring, Liver Transplantation, Antifungal Agents. 10 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Voriconazole is a triazole antifungal, primarily metabolized by the liver, and poses a dosing challenge in patients with liver impairment. Although the manufacturer recommends a maintenance dose reduction for mild‐to‐moderate hepatic dysfunction, no standardized recommendations exist for severe liver impairment. Prior evidence suggests a need for significant dose reduction in the setting of severe liver failure; however, there is limited data on empirical dosing in patients undergoing orthotopic liver transplant (OLT) evaluation and surgery.

Methods

This is a single‐center, retrospective cohort study assessing voriconazole dosing and therapeutic drug monitoring (TDM) in patients with advanced cirrhosis who received voriconazole during urgent OLT evaluation and/or surgery. Patients were included if voriconazole trough concentrations were collected at least 7 days after therapy initiation pre‐OLT or at least 5 days post‐OLT. The target therapeutic range was defined as 1–4 mcg/mL. The primary outcome was the distribution of voriconazole trough concentrations in the pre‐ and post‐transplant cohorts.

Results

The pre‐OLT cohort comprised 76 patients with 124 concentrations, and the post‐OLT cohort comprised 36 patients with 71 concentrations. As anticipated, the pre‐OLT group exhibited more abnormal liver enzymes and a high median Model for End‐Stage Liver Disease (MELD) score of 35 (Interquartile Range (IQR) 29.5–40). In the pre‐OLT setting, doses less than 2 mg/kg/dose were more likely associated with therapeutic voriconazole concentrations. Supratherapeutic concentrations were observed in 41 patients (average dose of 2.4 mg/kg/dose), of which five patients required therapy interruption. In the post‐OLT group, only 23 of 71 concentrations fell within the therapeutic range, with an average dose of 2.8 mg/kg/dose.

Conclusion

We found that empiric voriconazole dosing in patients with advanced cirrhosis undergoing OLT evaluation should not exceed 2 mg/kg/dose initially to mitigate the risk of drug accumulation and potential toxicity. In post‐OLT patients, it is reasonable to consider reverting to standard manufacturer‐recommended dosing. Given the pharmacokinetic variability observed, TDM is essential for effective and safe management in this high‐risk patient population.

Subjects

MeSH terms (MEDLINE)

VoriconazoleDrug MonitoringLiver TransplantationAntifungal AgentsHumansRetrospective StudiesFemaleMaleMiddle AgedLiver CirrhosisDose-Response Relationship, DrugCohort StudiesAged

Author keywords

cirrhosisliver transplanttherapeutic drug monitoringvoriconazole

Substances

VoriconazoleAntifungal Agents

Authors and institutions

  • Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA.
  • Center for Health Data Science and Analytics, Houston Methodist Hospital, Houston, Texas, USA.
  • Department of Surgery, Weill Cornell Medical College, New York, New York, USA.
  • Department of Surgery, Houston Methodist Hospital, Houston, Texas, USA.
  • J.C. Walter, Jr. Transplant Center, Houston Methodist Hospital, Houston, Texas, USA.
  • Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.

ORCID profiles: Wesley J Hoffmann, Shemual Tsai, Luma Succar, Aarjav Sanghvi, Stephen L Jones, Ashton A Connor, Constance M Mobley, R Mark Ghobrial, Masayuki Nigo

Cite

APA

Hoffmann, W. J., Tsai, S., Succar, L., Sanghvi, A., Jones, S. L., Connor, A. A., Mobley, C. M., Ghobrial, R. M., & Nigo, M. (2026). Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(7). https://doi.org/10.1002/phar.70176

Vancouver

Hoffmann WJ, Tsai S, Succar L, Sanghvi A, Jones SL, Connor AA, et al. Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(7). doi:10.1002/phar.70176

BibTeX
@article{Hoffmann2026,
  author = {Hoffmann, Wesley J and Tsai, Shemual and Succar, Luma and Sanghvi, Aarjav and Jones, Stephen L and Connor, Ashton A and Mobley, Constance M and Ghobrial, R Mark and Nigo, Masayuki},
  title = {Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  volume = {46},
  number = {7},
  doi = {10.1002/phar.70176}
}
Start for free →